In this Issue

• Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona
• Make-or-Break Moment Looms for Compass Pathways
• Makary Outlines Vision for Faster Drug Approvals
• RFK Jr. Details Teenage Acid Trip That Preceded Years of Addiction
• Enthea Ventures into Oregon’s Psilocybin Services
• A Neuroimmune Theory of Psychedelic Action?
• Pilot Study Explores Psilocybin for Mood Dysfunction in Parkinson’s Disease
• and more…

***

A few weeks ago I (Josh Hardman) had the privilege of attending a Design Thinking Workshop at IESE Business School in Barcelona as part of PsyPal, an EU-funded project that revolves around a study of psilocybin therapy for psychological distress in palliative care patients. (For a refresher on the project, see European Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients, and the project website.)

In a format that seems to be increasingly popular among psychedelics-focused meets, we worked in smaller groups to identify challenges and opportunities with respect to specific stakeholder groups, before feeding back to the larger group.

It was an interesting time to be surrounded by predominantly European attendees and researchers, who have a noticeably collaborative approach to decision-making and project-scoping.

There’s plenty going on in Europe, despite headlines (including ours) often focusing on the U.S. While some European research groups and projects might be less renowned, you can be sure I will overcome their modesty in the coming weeks to share a number of very exciting updates from the continent. Stay tuned.

***

Make-or-Break Moment Looms for Compass

Earlier this week, Compass Pathways announced that it has dosed the last patient in its first Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD), dubbed COMP 005 (NCT05624268).

That announcement starts the readout clock ticking, given that the study has a primary endpoint of COMP360 psilocybin vs. placebo MADRS change from baseline at week 6. That means we should expect to learn the headline result from the study, at least up to week 6, in the second half of June…

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…